Study Title (official): GOG 3020: Clovis Oncology CO-338-337 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib in combination with Nivolumab versus Rucaparib versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Objective of the study (Lay terms): After a positive response to initial chemotherapy treatment, investigators want to learn if taking a combination of a PARP inhibitor (rucaparib) and an anti- PD-1 inhibitor (nivolumab) after patient finishes initial chemotherapy helps to prevent cancer recurrence.
Principal Investigator: Sanaz Memarzadeh, MD, PhD
Department: UCLA Department of OBGYN
For enrollment or criteria information, please contact:
For additional information regarding inclusion and exclusion criteria > ClinicalTrials.gov